Ophthalmology. Retina最新文献

{"title":"PDE6A-Associated Retinitis Pigmentosa, Clinical Characteristics, Genetics, and Natural History.","authors":"Shaima Awadh Hashem, Michalis Georgiou, Genevieve Wright, Yu Fujinami-Yokokawa, Yannik Laich, Malena Daich Varela, Thales A C de Guimaraes, Omar A Mahroo, Andrew R Webster, Kaoru Fujinami, Michel Michaelides","doi":"10.1016/j.oret.2024.08.018","DOIUrl":"10.1016/j.oret.2024.08.018","url":null,"abstract":"<p><strong>Purpose: </strong>To analyze the genetics, clinical characteristics, and natural history of PDE6A-associated retinitis pigmentosa.</p><p><strong>Design: </strong>Retrospective, longitudinal, observational cohort study.</p><p><strong>Participants: </strong>Patients with molecularly confirmed PDE6A-associated retinal dystrophy in a single tertiary referral center.</p><p><strong>Methods: </strong>Review of medical records and retinal imaging, including fundus autofluorescence (FAF) imaging and spectral-domain OCT. Genetic results were reviewed, and the detected variants were assessed.</p><p><strong>Main outcome measures: </strong>Molecular genetic testing, clinical findings including best-corrected visual acuity (BCVA), qualitative and quantitative retinal imaging analysis.</p><p><strong>Results: </strong>Sixteen patients (32 eyes) were identified and evaluated longitudinally. Genetic analysis identified 14 variants in the PDE6A gene, including 8 novel variants. The mean age (± standard deviation, range) was 34.8 years (± 17.4, 12-76) at baseline, with a mean follow-up time of 4.8 years. Best-corrected visual acuity was 0.45 ± 0.45 logarithm of the minimum angle of resolution (logMAR) (range 0.0-1.6) at baseline and 0.65 ± 0.7 logMAR (range 0.0-2.3) at the last visit. Best-corrected visual acuity was similar among eyes in 88% of patients. A hyperautofluorescent ring was observed on FAF in 50% and 43.8% of the eyes at baseline and follow-up visit, respectively, with a mean area of 9.7 ± 4.5 mm² at baseline and mean of 8.6 ± 4.8 mm² at the follow-up visit. Mean horizontal ellipsoid zone width (EZW) at baseline was 1765 ± 1093 μm, which decreased to 1580 ± 1077 μm at follow-up. Eighteen eyes exhibited cystoid macular edema at baseline (56%), and 17 eyes (53%) at follow-up. There were statistically significant changes during the follow-up period in terms of BCVA, hyperautofluorescent ring area, and the EZW.</p><p><strong>Conclusions: </strong>This study highlights the natural history of PDE6A-retinopathy. Most patients in this cohort had mild BCVA loss, and slowly progressive disease, based on FAF and OCT measurements.</p><p><strong>Financial disclosure(s): </strong>Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.</p>","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":null,"pages":null},"PeriodicalIF":4.4,"publicationDate":"2024-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142110361","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessment of Baseline Ultrawidefield Fluorescein Angiographic Quantitative Leakage Parameters with Ultrawidefield Fundus Features and Clinical Parameters in Diabetic Retinopathy in Protocol AA.","authors":"Justis P Ehlers, Kristin Josic, Sari Yordi, Alison Martin, Sunil K Srivastava, Jenifer K Sun","doi":"10.1016/j.oret.2024.08.015","DOIUrl":"10.1016/j.oret.2024.08.015","url":null,"abstract":"<p><strong>Purpose: </strong>Evaluate quantitative leakage parameters on ultrawidefield fluorescein angiography (UWF-FA) images and explore their association with Diabetic Retinopathy Severity Scale (DRSS), predominantly peripheral lesions (PPLs), visual acuity, and clinical characteristics.</p><p><strong>Design: </strong>A post hoc analysis of baseline UWF-FA images in the DRCR Retina Network observational study Protocol AA.</p><p><strong>Participants: </strong>A total of 575 eyes from 384 adults across 38 sites in the United States and Canada with gradable UWF-FA.</p><p><strong>Methods: </strong>A machine learning-enhanced feature extraction platform provided initial leakage segmentation of UWF-FA images sequentially reviewed and corrected by 2 certified readers for segmentation accuracy. Ultrawidefield fluorescein angiography leakage was measured in 5 retinal zones: panretinal (entire retina), central macular (3-disc diameter fovea-centered circle), posterior pole (6-disc diameter fovea-centered circle), peripheral (outside 6-disc diameter circle), and widefield far peripheral (outside 9-disc diameter circle); associations with clinical factors were evaluated with marginal beta regression models.</p><p><strong>Main outcome measures: </strong>Ultrawidefield fluorescein angiography leakage index, calculated as the area with leakage divided by the analyzable retinal area.</p><p><strong>Results: </strong>The mean quantitative leakage index was 3.5% for panretinal, 6.6% for macular, 4.8% for posterior pole, 3.3% for peripheral, and 2.8% for widefield far peripheral retinal zones. Panretinal leakage was associated with DRSS (mean 2.2% for no to mild nonproliferative diabetic retinopathy [NPDR], 3.4% for moderate NPDR, 4.2% for moderately severe NPDR, 4.8% for severe NPDR, and 5.1% for proliferative diabetic retinopathy; P < 0.001), hemoglobin A1C (HbA1c) (3.2% for HbA1c < 8% vs. 3.8% for HbA1c ≥ 8%; P = 0.01 for continuous HbA1c), visual acuity (3.3% for 20/25 or better vs. 4.7% for 20/32 or worse; continuous P < 0.001), and UWF-FA-PPL types of intraretinal microvascular abnormality (4.3% vs. 3.3%; P = 0.005) or new vessels elsewhere (5.7% vs. 3.4%; P = 0.003). Diabetic retinopathy severity was also statistically significant for leakage within all retinal zones (P < 0.001); eyes with noncentral diabetic macular edema (DME) versus no DME had higher mean leakage in the central macular (11.2% vs. 5.9%; P = 0.005) and posterior pole regions (9.2% vs. 4.2%; P = 0.002).</p><p><strong>Conclusions: </strong>Quantitative UWF-FA leakage analysis identified associations between leakage and DRSS, visual acuity, and presence of DME. In the future, quantitative UWF-FA leakage parameters may be explored as potential biomarkers for disease progression risk.</p><p><strong>Financial disclosure(s): </strong>Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.</p>","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":null,"pages":null},"PeriodicalIF":4.4,"publicationDate":"2024-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142110357","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Interreader and Intermodality Variability in Macular Atrophy Quantification in Neovascular Age-related Macular Degeneration: Comparison of 6 Imaging Modalities.","authors":"Enrico Borrelli, Chiara Olivieri, Sonia Serafino, Andrea Coletto, Federico Ricardi, Giovanni Neri, Paola Marolo, Michele Reibaldi","doi":"10.1016/j.oret.2024.08.017","DOIUrl":"10.1016/j.oret.2024.08.017","url":null,"abstract":"<p><strong>Purpose: </strong>Macular atrophy is a common complication in neovascular age-related macular degeneration (AMD) and is associated with poorer visual outcomes. This study evaluated interreader and intermodality variability in measuring macular atrophy in previously treated neovascular AMD eyes without exudation using 6 imaging modalities.</p><p><strong>Design: </strong>Prospective, cohort study.</p><p><strong>Participants: </strong>Thirty participants with previously treated neovascular AMD showing no signs of exudation at the time of enrollment and exhibiting macular atrophy.</p><p><strong>Methods: </strong>During the same clinic visit, patients were imaged using 6 different imaging modalities: color fundus photography (CFP; Clarus, Carl Zeiss Meditec), near-infrared imaging (NIR; Spectralis, Heidelberg Engineering), structural OCT (Spectralis, Heidelberg Engineering), green fundus autofluorescence (GAF; Clarus, Carl Zeiss Meditec), blue fundus autofluorescence (BAF; Spectralis, Heidelberg Engineering), and pseudocolor imaging (MultiColor; Spectralis, Heidelberg Engineering). Two readers independently measured the macular atrophy area.</p><p><strong>Main outcome measures: </strong>Interreader and intermodality agreement.</p><p><strong>Results: </strong>The 95% coefficient of repeatability was 5.98 mm² for CFP, 4.46 mm² for MultiColor, 3.90 mm² for BAF, 3.92 mm² for GAF, 4.86 mm² for NIR, and 3.55 mm² for OCT. Similarly, the coefficient of variation was lowest for OCT-based grading at 0.08 and highest for NIR-based grading at 0.28. Accordingly, the intraclass correlation coefficient was 0.742 for CFP, 0.805 for MultiColor, 0.857 for BAF, 0.850 for GAF, 0.755 for NIR, and 0.917 for OCT. The 6 different imaging modalities presented measurements with different mean values, with only a limited number of comparisons not significantly different between the instruments, although measurements were correlated. The largest size of macular atrophy was measured with structural OCT-based grading (median = 4.65 mm²; interquartile range [IQR] = 4.78 mm²) and the smallest was with CFP-based grading (median = 3.86 mm²; IQR = 5.06 mm²). Inconsistencies arose from various factors.</p><p><strong>Conclusions: </strong>In patients with neovascular AMD, macular atrophy measurements vary significantly depending on the imaging technique used. Color fundus photography-based assessments yielded the smallest macular atrophy sizes, whereas structural OCT-based assessments produced the largest. These discrepancies stem from both the inherent limitations of each modality in assessing retinal pigment epithelial atrophy and factors related to neovascularization, such as the coexistence of fibrosis.</p><p><strong>Financial disclosure(s): </strong>Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.</p>","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":null,"pages":null},"PeriodicalIF":4.4,"publicationDate":"2024-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142110360","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Interim Results of the Phase III Portal Extension Trial of the Port Delivery System with Ranibizumab in Neovascular Age-Related Macular Degeneration.","authors":"Peter A Campochiaro, David Eichenbaum, Margaret A Chang, W Lloyd Clark, Jordan M Graff, Sophie Le Pogam, Melina Cavichini Cordeiro, Shamika Gune, Mel Rabena, Natasha Singh, Stephanie Lin, Natalia Callaway","doi":"10.1016/j.oret.2024.05.021","DOIUrl":"10.1016/j.oret.2024.05.021","url":null,"abstract":"<p><strong>Objective: </strong>The Port Delivery System with ranibizumab (PDS) is approved in the United States for neovascular age-related macular degeneration (nAMD). Portal (NCT03683251) is evaluating long-term safety and tolerability of the PDS in patients with nAMD who completed the phase II Ladder (NCT02510794) or phase III Archway (NCT03677934) trials.</p><p><strong>Design: </strong>Multicenter, nonrandomized, open-label, extension clinical trial.</p><p><strong>Participants: </strong>All-PDS safety population (N = 555) comprises patients enrolled in Portal who completed Ladder or Archway. Because of data availability, efficacy population comprises Ladder-to-Portal patients only: patients who previously received PDS 10, 40, or 100 mg/mL pro re nata (as-needed [PRN]; n = 58, 62, and 59, respectively) or monthly intravitreal ranibizumab 0.5-mg injections (monthly ranibizumab; n = 41) in Ladder and subsequently enrolled in Portal.</p><p><strong>Methods: </strong>Ladder patients received PDS refill-exchanges PRN or monthly ranibizumab. Archway patients received PDS 100 mg/mL with fixed refill-exchanges every 24 weeks (Q24W) or monthly ranibizumab. Once enrolled in Portal, all patients receive PDS Q24W from day 1.</p><p><strong>Main outcome measures: </strong>Ocular adverse events of special interest (AESIs); changes from baseline in best-corrected visual acuity (BCVA) and center point thickness (CPT); supplemental ranibizumab treatment between refill-exchange procedures; and PDS Patient Preference Questionnaire results.</p><p><strong>Results: </strong>In the All-PDS safety population (mean follow-up, 111 weeks), 137 (24.7%) patients had ≥1 ocular AESI; most common were cataract (11.4%), vitreous hemorrhage (6.1%), and conjunctival thickening (bleb)/filtering bleb leak (6.3%). Endophthalmitis occurred in 11 of 555 (2.0%) patients. For Ladder-to-Portal patients previously treated with PDS 100 mg/mL or monthly ranibizumab, BCVA remained stable from baseline to month 48; mean (95% confidence interval) changes from baseline were 0.1 (-6.6 to 6.8; n = 31) and 2.3 (-9.4 to 14.1; n = 15) letters, respectively; CPT remained stable through month 48. Approximately 95% of patients did not need supplemental treatment before each refill-exchange for >2 years since Portal enrollment. Of Ladder-to-Portal previous monthly ranibizumab patients, 92% preferred the PDS over injections.</p><p><strong>Conclusions: </strong>Interim results from Portal suggest 4-year maintenance of visual/anatomic outcomes with PDS 100 mg/mL, with the PDS preferred to monthly injections. Long-term safety profile of the PDS is well characterized.</p><p><strong>Financial disclosure(s): </strong>Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.</p>","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":null,"pages":null},"PeriodicalIF":4.4,"publicationDate":"2024-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142110359","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and Safety of Efdamrofusp Alfa versus Aflibercept in Participants with Neovascular Age-Related Macular Degeneration: A Randomized, Double-Masked, Active-Controlled, Noninferiority, Phase II Trial.","authors":"Junran Sun, Yanping Song, Yuanyuan Gong, Liming Tao, Hong Wang, Xiangwen Shu, Ying Wen, Ling Cui, Jian Ye, Shujie Lu, Junjie Deng, Haoyu Li, Yihua Xu, Lei Qian, Zhifeng Wu, Yanlong Bi, Qinghuai Liu, Xiangzhong Xu, Miaoqin Wu, Jinglin Zhang, Jilong Hao, Jianping Tong, Hong Dai, Feng Wang, MingWei Zhao, Junfeng Mao, Chaopeng Li, Tao He, Cheng Pei, Xiaoling Liu, Xian Wang, Mingxin Li, Wei Wang, Qinxiang Zheng, Huaijin Guan, Hui Peng, Ke Fan, Wenfang Zhang, Dan Zhu, Songping Yu, Wenbin Wei, Lin Ding, Jinying Li, Peirong Lu, Ming Yan, Wei Liu, Huixun Jia, Xiaodong Sun","doi":"10.1016/j.oret.2024.08.014","DOIUrl":"10.1016/j.oret.2024.08.014","url":null,"abstract":"<p><strong>Purpose: </strong>To evaluate efficacy and safety of efdamrofusp alfa compared with aflibercept in neovascular age-related macular degeneration (nAMD).</p><p><strong>Design: </strong>Randomized, double-masked, multicenter, active-controlled, noninferiority phase II study.</p><p><strong>Participants: </strong>A total of 231 treatment-naive and previously treated participants with active choroidal neovascularization secondary to nAMD were enrolled.</p><p><strong>Methods: </strong>Eligible participants were randomized (1:1:1) to 2 mg efdamrofusp alfa, 4 mg efdamrofusp alfa, or 2 mg aflibercept groups. Participants in all groups received 3 initial monthly loading doses, followed by treatment every 8 weeks, with assessment every 4 weeks up to week 52.</p><p><strong>Main outcome measures: </strong>The primary end point was the mean best-corrected visual acuity (BCVA) change from baseline to week 36. The prespecified noninferiority margin was set as -5 letters (80% confidence interval [CI]).</p><p><strong>Results: </strong>Each treatment group included 77 participants. The mean BCVA changes from baseline to week 36 for 2 mg efdamrofusp alfa, 4 mg efdamrofusp alfa and aflibercept groups were +10.6, +11.4, and +12.0 letters, respectively; least squares mean difference were -1.4 (80% CI: -3.5 to 0.7) between 2 mg efdamrofusp alfa and aflibercept, and -0.6 (80% CI: -2.7 to 1.6) between 4 mg efdamrofusp alfa and aflibercept. Mean central retinal thickness changes were consistent across groups. Adverse event rate was comparable among the groups.</p><p><strong>Conclusions: </strong>Efdamrofusp alfa demonstrated noninferiority to aflibercept in BCVA improvement, accompanied by a similar safety profile.</p><p><strong>Financial disclosure(s): </strong>The author(s) have no proprietary or commercial interest in any materials discussed in this article.</p>","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":null,"pages":null},"PeriodicalIF":4.4,"publicationDate":"2024-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142110358","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Angiographic Characteristics in Mild Familial Exudative Vitreoretinopathy with Genetically Confirmed Autosomal Dominant Inheritance.","authors":"Misato Okamoto, Itsuka Matsushita, Tatsuo Nagata, Yoshihisa Fujino, Hiroyuki Kondo","doi":"10.1016/j.oret.2024.08.013","DOIUrl":"10.1016/j.oret.2024.08.013","url":null,"abstract":"<p><strong>Purpose: </strong>To determine the ultra-widefield fluorescein angiographic (UWFA) characteristics of patients with mild familial exudative vitreoretinopathy (FEVR) who had been confirmed to have pathogenic variants of the autosomal dominant (AD) genes of FEVR.</p><p><strong>Design: </strong>Single center, observational case series.</p><p><strong>Subjects and controls: </strong>Thirty-seven patients with mild FEVR from 27 families who had pathogenic variants of the Norrin/β-catenin genes were studied. The controls consisted of 32 family members who had been confirmed not to carry the pathogenic variants or had heterozygous variants of the autosomal recessive inheritance gene.</p><p><strong>Methods: </strong>Sixty-four UWFA images from the patients were compared with 60 UWFA images from the controls. The relative length of the temporal retina to the peripheral avascular retina was determined. The cut-off ratio of the relative lengths for a clinically significant avascular retina (csAR) associated with AD-FEVR was determined using the receiver operating characteristic (ROC) curves.</p><p><strong>Main outcome measures: </strong>The presence or absence of 6 peripheral vascular changes (csAR, V-shaped vascular notch, brushy vascular ends, vascular stain, loop vessels or anastomosis, and capillary telangiectasia) were compared between the patients and the controls.</p><p><strong>Results: </strong>The csAR was set at > 12% of the length from the ora serrata to the optic disc. The patients with AD-FEVR had more frequent retinal changes than the controls for the V-shaped vascular notch (69% vs. 2%; P < 0.001), brushy vascular ends (78% vs. 3%; P < 0.001), csAR (83% vs. 22%; P < 0.001), and vascular stain (70% vs. 35%, P < 0.001). Loop vessels and/or anastomosis of peripheral vessels were found significantly less frequently in the patients than in the controls (39% vs. 73%; P < 0.001). No significant difference was found for capillary telangiectasia between the 2 groups. The combination of the V-shaped vascular notches, brushy vascular ends, and csAR had a sensitivity of 82.8% and specificity of 98.3%, with the highest ROC curve of 0.9.</p><p><strong>Conclusions: </strong>The combination of V-shaped vascular notch, brushy vascular ends, and csAR can be used as a biomarker for patients with AD-FEVR who have pathogenic variants of the Norrin/β-catenin genes. These findings will allow more accurate segregation analysis in FEVR families and allow better genetic counseling.</p><p><strong>Financial disclosure(s): </strong>Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.</p>","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":null,"pages":null},"PeriodicalIF":4.4,"publicationDate":"2024-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142093653","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Plaque Brachytherapy in a Patient with Diffuse Choroidal Hemangioma.","authors":"Subhav Pershad, Vijay Anand P Reddy, Santosh G Honavar","doi":"10.1016/j.oret.2024.07.022","DOIUrl":"https://doi.org/10.1016/j.oret.2024.07.022","url":null,"abstract":"","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":null,"pages":null},"PeriodicalIF":4.4,"publicationDate":"2024-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142056221","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outer Retinal Tubulations in Bietti Crystalline Dystrophy.","authors":"Shiyi Yin, Jinyuan Wang, Wenbin Wei","doi":"10.1016/j.oret.2024.07.018","DOIUrl":"https://doi.org/10.1016/j.oret.2024.07.018","url":null,"abstract":"","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":null,"pages":null},"PeriodicalIF":4.4,"publicationDate":"2024-08-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142056220","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Amoeboid Retinal Lesions and Macular Atrophy in RDH12 Mutation.","authors":"Marina Ger, Srikanta Kumar Padhy","doi":"10.1016/j.oret.2024.07.019","DOIUrl":"https://doi.org/10.1016/j.oret.2024.07.019","url":null,"abstract":"","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":null,"pages":null},"PeriodicalIF":4.4,"publicationDate":"2024-08-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142056218","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-Term Redetachment Rates of Pneumatic Retinopexy versus Pars Plana Vitrectomy in Retinal Detachment: A PIVOT Post Hoc Analysis.","authors":"Tugche S Chen, Yasmin Motekalem, Isabela Martins Melo, Roxane J Hillier, Alan R Berger, Louis R Giavedoni, David T Wong, Filiberto Altomare, Rajeev H Muni","doi":"10.1016/j.oret.2024.08.011","DOIUrl":"10.1016/j.oret.2024.08.011","url":null,"abstract":"<p><strong>Purpose: </strong>To assess long-term redetachment rates of the Pneumatic Retinopexy versus Vitrectomy for the Management of Primary Rhegmatogenous Retinal Detachment Outcomes Randomized Trial (PIVOT).</p><p><strong>Design: </strong>Randomized controlled trial.</p><p><strong>Subjects: </strong>PIVOT trial participants.</p><p><strong>Methods: </strong>This study was performed at St. Michael's Hospital, Unity Health Toronto, Toronto, Canada. PIVOT trial participants who had undergone either pneumatic retinopexy (PnR) or pars plana vitrectomy (PPV) for rhegmatogenous retinal detachment (RRD) repair with a minimum follow-up of 2 years were assessed for long-term redetachment by chart review or telephone interview. The latter was the only accepted method for those with <2 years of follow-up. Patients were only eligible if no reintervention to reattach the retina was performed within the first year of the initial procedure.</p><p><strong>Main outcome measures: </strong>Long-term redetachment rates for PnR vs. PPV after RRD repair.</p><p><strong>Results: </strong>Sixty-one participants who underwent PPV and 62 who underwent PnR were analyzed. The long-term redetachment rates were 0% and 1.61% (1/62) in the PPV and PnR groups, respectively (P = 0.32). The mean follow-up duration in years was 5.43 ± 3.60 vs. 5.51 ± 3.03 in the PPV and PnR groups, respectively.</p><p><strong>Conclusions: </strong>There was no statistically significant difference in long-term redetachment rates for PnR vs. PPV. Both procedures are durable treatment options for RRD over an extended period, rarely requiring additional intervention for redetachment.</p><p><strong>Financial disclosure(s): </strong>The author(s) have no proprietary or commercial interest in any materials discussed in this article.</p>","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":null,"pages":null},"PeriodicalIF":4.4,"publicationDate":"2024-08-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142056219","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}